Momenta Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to P...
December 11 2018 - 4:05PM
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology
company with a validated scientific platform focused on discovering
and developing novel therapeutics to treat rare, immune-mediated
diseases, today announced the closing of its underwritten public
offering of 20,000,000 shares of its common stock at the public
offering price of $11.50 per share, which includes the exercise in
full of the underwriter’s option to purchase additional shares of
common stock. The total gross proceeds from the offering are
approximately $230 million.
Goldman Sachs & Co. LLC acted as sole
book-running manager for the offering.
The offering was made pursuant to an effective
shelf registration statement on Form S-3 that was initially filed
with the U.S. Securities and Exchange Commission (SEC) on February
29, 2016. The final prospectus supplement has been filed with the
SEC and forms a part of the effective registration statement.
Copies of the final prospectus supplement and accompanying
prospectus relating to the offering may be obtained by contacting
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200
West Street, New York, New York 10282, or by telephone at (866)
471-2526 or e-mail at prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer
to sell, or the solicitation of an offer to buy, nor shall there be
any sale of shares of these securities in any state or jurisdiction
in which such offer, solicitation, or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction.
About Momenta
Momenta is a biotechnology company with a
validated innovative scientific platform focused on discovering and
developing novel therapeutics to treat rare, immune-mediated
diseases. Momenta's lead product candidate, M281, is a potentially
best-in-class anti-FcRn antibody; M254, is a hyper-sialylated human
immunoglobulin (hsIgG) designed as a high potency alternative to
intravenous immunoglobulin (IVIg); and M230 (CSL730), is a
potential first-in-class novel recombinant Fc multimer being
developed in collaboration with CSL. Momenta also has a focused
pipeline of two biosimilar candidates: M923, Momenta's wholly-owned
proposed biosimilar to HUMIRA®, and M710, a proposed biosimilar to
EYLEA® being developed in collaboration with Mylan. Momenta's two
FDA-approved complex generic products, enoxaparin sodium injection
and Glatopa® (glatiramer acetate injection), are marketed by its
collaboration partner, Sandoz.
Momenta's logo, trademarks, and service marks
are the property of Momenta Pharmaceuticals, Inc. All other trade
names, trademarks, or service marks are property of their
respective owners.
Forward Looking
Statements
Statements in this press release regarding
management's future expectations, beliefs, intentions, goals,
strategies, plans or prospects, are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements relating to
market potential and product revenues of the Company's product
candidates. Forward-looking statements may be identified by words
and phrases such as "advance," "anticipate," "being developed,"
"believe," "continue," "expect," "guidance," "look forward to,"
"may," "plan," "possible," "potential," "progress," "propose,"
"remains," "target," "will," "working toward" and other similar
words or expressions, or the negative of these words or similar
words or expressions. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors, including
those referred to under the section "Risk Factors" in the Company's
Quarterly Report on Form 10-Q for the quarter ended September
30, 2018, filed with the Securities and Exchange
Commission, as well as other documents that may be filed by the
Company from time to time with the Securities and Exchange
Commission. As a result of such risks, uncertainties and
factors, the Company's actual results may differ materially from
any future results, performance or achievements discussed in or
implied by the forward-looking statements contained
herein. The Company is providing the information in this press
release as of this date and assumes no obligations to update the
information included in this press release or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
INVESTOR
CONTACT:Young KwonMomenta
Pharmaceuticals1-617-395-4964IR@momentapharma.com |
MEDIA
CONTACT:Karen SharmaMacDougall Biomedical
Communications1-781-235-3060Momenta@macbiocom.com |
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2023 to Apr 2024